Revenue: As of FY2025 Q4, the actual value is USD 994.23 M, beating the estimate of USD 986.98 M.EPS: As of FY2025 Q4, the actual value is USD -5.62, missing the estimate of USD 1.3533.EBIT: As of FY2025 Q4, the actual value is USD -260.68 M.<h3>Fourth-Quarter 2025 Financial Performance</h3><h4>Consolidated Results</h4><ul><li>Total Revenue: Charles River Laboratories International, Inc. reported $994.2 million in revenue for the fourth quarter of 2025, a decrease of 0.8% from $1,002.5 million in the fourth quarter of 2024. Foreign currency translation positively impacted reported revenue by 1.9%, while a divestiture reduced it by 0.1%. On an organic basis, revenue declined 2.6%, primarily due to the Discovery and Safety Assessment (DSA) and Manufacturing Solutions (Manufacturing) segments .</li><li>GAAP Operating Margin: The GAAP operating margin was -28.5%, compared to -16.7% in the fourth quarter of 2024 .</li><li>GAAP Net Loss: The GAAP net loss available to common shareholders was - $276.6 million, or - $5.62 per diluted share, for the fourth quarter of 2025, compared to a net loss of - $215.7 million, or - $4.22 per diluted share, for the same period in 2024. This included non-cash intangible asset impairments of $211.0 million (or $3.22 per share) and a non-cash goodwill impairment of $165.0 million (or $3.35 per share) in the fourth quarter of 2025 .</li><li>Non-GAAP Operating Margin: The non-GAAP operating margin decreased to 18.1% from 19.9% in the fourth quarter of 2024 .</li><li>Non-GAAP Net Income: Non-GAAP net income was $118.8 million, a decrease of 13.0% from $136.6 million in the fourth quarter of 2024 .</li></ul><h4>Segment Performance (Fourth Quarter 2025)</h4><ul><li>Research Models and Services (RMS):<ul><li>Revenue: $206.3 million, an increase of 1.0% from $204.3 million in the fourth quarter of 2024. Organic revenue decreased by 0.9% .</li><li>GAAP Operating Margin: -33.6%, down from 6.7% in the fourth quarter of 2024 due to an intangible asset impairment .</li><li>Non-GAAP Operating Margin: Decreased to 21.9% from 22.8% .</li></ul></li><li>Discovery and Safety Assessment (DSA):<ul><li>Revenue: $591.6 million, a decrease of 2.0% from $603.3 million in the fourth quarter of 2024. Organic revenue decreased by 3.3% .</li><li>GAAP Operating Margin: Increased to 14.3% from 10.4% in the fourth quarter of 2024 .</li><li>Non-GAAP Operating Margin: Decreased to 20.1% from 24.7% in the fourth quarter of 2024 .</li></ul></li><li>Manufacturing Solutions (Manufacturing):<ul><li>Revenue: $196.4 million, an increase of 0.7% from $194.9 million in the fourth quarter of 2024. Organic revenue decreased 2.1% .</li><li>GAAP Operating Margin: -115.9%, compared to -93.6% in the fourth quarter of 2024 due to larger impairments .</li><li>Non-GAAP Operating Margin: Increased to 32.1% from 28.7% in the fourth quarter of 2024 .</li></ul></li></ul><h3>Full-Year 2025 Financial Performance</h3><h4>Consolidated Results</h4><ul><li>Total Revenue: Charles River Laboratories International, Inc. reported $4.02 billion for the full year 2025, a decrease of 0.9% from $4.05 billion in 2024. Organic revenue declined by 1.6% .</li><li>GAAP Operating Margin: Decreased to 0.6% from 5.6% in 2024 .</li><li>Non-GAAP Operating Margin: Decreased to 19.8% from 19.9% in 2024 .</li><li>GAAP Net Loss: - $144.3 million, compared to net income of $10.3 million in 2024 .</li><li>Non-GAAP Net Income: $512.3 million, a decrease of 3.9% from $532.9 million in 2024 .</li></ul><h4>Cash Flow (Full-Year 2025)</h4><ul><li>Net Cash Provided by Operating Activities: $737.6 million, compared to $734.6 million in 2024 .</li><li>Capital Expenditures: - $219.2 million, compared to - $233.0 million in 2024 .</li></ul><h3>2026 Guidance</h3>查尔斯河 (Charles River Laboratories International, Inc.) anticipates 2026 reported revenue growth to be at least flat to +1.5%, with organic revenue growth expected to be -1.0% to at least flat . Non-GAAP earnings per share are projected to increase by approximately 4% to 9%, reaching an estimated range of $10.70 to $11.20 . This outlook assumes a return to organic revenue growth in the second half of 2026 for both consolidated results and the DSA segment, along with increased revenue in the Manufacturing segment .

Charles River Laboratorie | 8-K: FY2025 Q4 Revenue Beats Estimate at USD 994.23 M